37. Vizimpro

Pfizer HQ
(Pfizer)

Active ingredient: dacomitinib 
Disease: EGFR-mutated non-small cell lung cancer 
Peak sales estimate: n/a
Approved: Sept. 27 
Company: Pfizer 

The scoop: It took a while, but Pfizer’s Vizimpro finally crossed the regulatory finish line this fall—a feat that looked unlikely back in 2014. That year, the drug failed a pair of studies pitting it against Roche’s Tarceva. But Pfizer rebounded, and last year it trumpeted a phase 3 win at ASCO showing Vizimpro could top fellow EGFR drug Iressa from AstraZeneca at delaying cancer growth in newly diagnosed patients. Now, the drug is rolling out with a price tag of $12,400 per month alongside a slew of other new Pfizer oncology approvals. But it’ll have to duke it out with drugs including Tarceva and AstraZeneca’s hot-selling Tagrisso to find success in the marketplace. — Carly Helfand 

37. Vizimpro
Read more on

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.